Vanda Pharmaceuticals Inc. develops and commercializes biopharmaceutical therapies, with company updates centered on prescription products and clinical or regulatory programs. Recurring news includes financial results, Fanapt sales trends, HETLIOZ commercialization, the U.S. availability of NEREUS (tradipitant) for prevention of vomiting induced by motion, and FDA approval of BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia.
Vanda news also covers development activity for imsidolimab in generalized pustular psoriasis, product-access and commercial-channel updates, investor conference participation, regulatory-policy statements, and corporate governance changes such as board appointments.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its second quarter 2020 financial results on August 5, 2020, after market close. A conference call is scheduled for 4:30 PM ET the same day, where management will discuss the results and corporate activities. Investors can participate by calling 1-888-771-4371 domestically or 1-847-585-4405 internationally, using passcode 49854840. The call will also be streamed live and archived on Vanda's website.